Why doesn’t Panobinostat treat tyrosinemia?

Panobinostat (Panobinostat) is a histone deacetylase inhibitor mainly used to treat multiple myeloma. Its therapeutic mechanism is related to the proliferation and survival of cancer cells, which is significantly different from the therapeutic target of tyrosinemia, so it cannot be used to treat tyrosinemia.

Tyrosinemia is an inherited metabolic disease, mainly due to a lack or defective enzyme that prevents the normal metabolism of tyrosine in the body, resulting in the accumulation of tyrosine in the blood. Panobinostat mainly inhibits the growth of cancer cells by inhibiting histone deacetylase and regulating gene expression. However, this is not relevant to the pathophysiological mechanism of tyrosinemia.

Treatment of tyrosinemia usually requires restoring normal tyrosine metabolism through specific metabolic pathways, such as supplementing missing enzymes or promoting tyrosine metabolism through other metabolic pathways. Panobinostat does not involve these mechanisms and therefore cannot be used to treat tyrosinemia.

Treatment of tyrosinemia usually requires a more specialized approach involving the regulation and repair of metabolic pathways, as well as specific medical and nutritional management. Therefore, although panobinostat has shown good effects in the field of cancer treatment, its mechanism of action limits its application in the treatment of tyrosinemia.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.